Novo Nordisk Sues Lilly Over False Advertising Claims Amid Obesity War

What happened

Novo Nordisk has filed a lawsuit in U.S. federal court accusing Eli Lilly of false advertising by claiming its weight-loss drugs outperform Novo's, adding legal risk to their competitive rivalry. The suit comes as Lilly's obesity franchise—led by Zepbound and the newly launched oral Foundayo—generates explosive growth, with Q1 2026 revenue up 56% and EPS up 170%. However, Lilly's financials reveal a more fragile picture: volume grew 65% but price declined 13%, gross margin slipped 60bps to 81.9%, and the company relies on favorable one-time adjustments to reported economics. The DeepValue report rates Lilly a WAIT with no margin of safety at $1,169 (41.5x P/E), arguing the stock prices in clean access economics that current evidence does not fully support. The lawsuit could distract management, amplify pricing pressures, and provide ammunition for PBMs and payers to demand further concessions, intensifying the risk that volume growth does not translate into durable earnings expansion.

Implication

The false advertising suit adds incremental legal risk to an already stretched valuation. With P/E at 41.5x and net debt rising, any disruption to marketing claims or PBM relationships could amplify the price headwind. Investors should monitor Q3 and Q4 results for realized price trends; a repeat of -13% price decline would break the thesis. Entry point remains unattractive above $1,025.

Thesis delta

The lawsuit does not alter the fundamental thesis that Lilly's obesity portfolio is best-in-class, but it introduces a new layer of uncertainty around commercialization execution. Previously, the key risk was whether access expansion would come at the cost of pricing. Now, marketing disputes could accelerate price concessions or impair prescription momentum, especially for Foundayo's launch. The call remains WAIT, but the bear-case scenario becomes slightly more likely given the legal overhang.